EGF RECEPTOR PHOSPHORYLATION STATUS FOR DISEASE TREATMENT

摘要

This invention relates, e.g., to a method for predicting the response of a subject having a disease or condition mediated by EGFR (e.g., a cancer of epithelial origin, such as NSCLC) to an EGFR kinase inhibitor (e.g., Iressa® (gefitinib) and/or Tarceva® (erlotinib)). The method comprises measuring the amount of phosphorylation at residues Y1068 and T1148 in EGFR in a sample from the subject, wherein a significantly elevated level of phosphorylation at the two residues compared to a baseline value indicates that the subject is likely to be responsive to an agent that inhibits the kinase activity of EGFR. Other sites of phosphorylation that can be employed are also disclosed, including other residues in EGFR, as well as sites in other proteins of the EGFR signaling cascade.